Matches in Wikidata for { <http://www.wikidata.org/entity/Q37508315> ?p ?o ?g. }
- Q37508315 description "article científic" @default.
- Q37508315 description "article scientifique" @default.
- Q37508315 description "articolo scientifico" @default.
- Q37508315 description "artigo científico" @default.
- Q37508315 description "artículu científicu espublizáu en 2013" @default.
- Q37508315 description "bilimsel makale" @default.
- Q37508315 description "bài báo khoa học" @default.
- Q37508315 description "scientific article published on June 2013" @default.
- Q37508315 description "vedecký článok" @default.
- Q37508315 description "vetenskaplig artikel" @default.
- Q37508315 description "videnskabelig artikel" @default.
- Q37508315 description "vědecký článek" @default.
- Q37508315 description "wetenschappelijk artikel" @default.
- Q37508315 description "wissenschaftlicher Artikel" @default.
- Q37508315 description "наукова стаття, опублікована в червні 2013" @default.
- Q37508315 description "научни чланак" @default.
- Q37508315 description "مقالة علمية نشرت في يونيو 2013" @default.
- Q37508315 name "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 name "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 name "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 type Item @default.
- Q37508315 label "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 label "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 label "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 prefLabel "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 prefLabel "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 prefLabel "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 P1433 Q37508315-D3CAF2A5-65CA-43FD-B3E4-2254BE937AC1 @default.
- Q37508315 P1476 Q37508315-30AA27B8-EFE0-4AFD-AC76-6D48B753C0E3 @default.
- Q37508315 P2093 Q37508315-18611BE5-6B7A-417F-8178-E50394C72AE6 @default.
- Q37508315 P2093 Q37508315-1AE5665E-5BF1-4271-AB00-4407805998E1 @default.
- Q37508315 P2093 Q37508315-1C2D7329-96DB-4466-9369-48C2A7D6C128 @default.
- Q37508315 P2093 Q37508315-2CE5403F-D9A4-4505-BE74-15E827B277BB @default.
- Q37508315 P2093 Q37508315-7DB0F731-8244-4288-AD97-0B42BA65A327 @default.
- Q37508315 P2093 Q37508315-898E2D70-4F98-4778-A5EB-F0AC12BCD8D6 @default.
- Q37508315 P2093 Q37508315-A0229A10-EF77-4532-AEC7-3498106FF948 @default.
- Q37508315 P2093 Q37508315-D69539D3-53AE-4663-AC04-BDFF90BC0E42 @default.
- Q37508315 P2093 Q37508315-FE976344-2F55-41EC-859E-B9672F4FDD15 @default.
- Q37508315 P2860 Q37508315-186302BB-4905-4C66-BF98-BFCE7885683A @default.
- Q37508315 P2860 Q37508315-19AEF9B7-9172-4C23-B763-AC032BC5261C @default.
- Q37508315 P2860 Q37508315-1BB27222-D264-4126-A3FB-88FD4B3A8179 @default.
- Q37508315 P2860 Q37508315-2882DFE5-DF20-4855-907E-3DB5FFA1744C @default.
- Q37508315 P2860 Q37508315-60C43120-EE1F-4F67-9384-C2D5876DFB17 @default.
- Q37508315 P2860 Q37508315-731AE7CF-AA94-44E8-A36F-E96A0E3810B1 @default.
- Q37508315 P2860 Q37508315-81FA0EA6-E80F-4699-B565-3A5FF19D045D @default.
- Q37508315 P2860 Q37508315-A944C6EB-236D-4F47-9FD8-59D6196AB2CC @default.
- Q37508315 P2860 Q37508315-AC9A677C-31CF-48D8-AD24-41FAE7C5C5B0 @default.
- Q37508315 P2860 Q37508315-CC06DEB0-9512-449B-BAE8-7D5C06648553 @default.
- Q37508315 P2860 Q37508315-D3CC9DC3-89F8-4208-8FB5-4E445808975B @default.
- Q37508315 P2860 Q37508315-E7858B21-3D63-4ECC-A804-184AAFD5B102 @default.
- Q37508315 P2860 Q37508315-E94EEA76-3285-4C21-8C50-BB0203FE6039 @default.
- Q37508315 P2860 Q37508315-FCE46136-141F-4FC5-BCAB-B1E7C1EC6CD7 @default.
- Q37508315 P2860 Q37508315-FF375047-38F2-485E-B243-BD502AF11454 @default.
- Q37508315 P304 Q37508315-C783DD04-7AB3-4C7E-91F5-DC613EB8ED43 @default.
- Q37508315 P31 Q37508315-6BB05DE1-5611-4E68-812A-3D73818F0D26 @default.
- Q37508315 P356 Q37508315-026E808E-F77C-4BB0-B575-9608B4AFC2F0 @default.
- Q37508315 P433 Q37508315-41932E0A-7825-4882-886C-231363D5D642 @default.
- Q37508315 P478 Q37508315-6A804245-B773-4592-9626-6AE8B7F7CE32 @default.
- Q37508315 P577 Q37508315-94C1A19A-1CA2-4262-828D-B7B5A2454761 @default.
- Q37508315 P698 Q37508315-A486A372-6D5F-4703-9008-B0DC3DEB8E37 @default.
- Q37508315 P921 Q37508315-7BAE2927-9E86-4F20-942C-DBDEDF789BD6 @default.
- Q37508315 P921 Q37508315-E9D02118-BD52-4D20-BC49-F21F0EE6054A @default.
- Q37508315 P932 Q37508315-C2567B6C-9A30-4546-9C14-3D443BC04CDF @default.
- Q37508315 P356 COC.0B013E3182467F22 @default.
- Q37508315 P698 22547007 @default.
- Q37508315 P1433 Q2886177 @default.
- Q37508315 P1476 "A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma" @default.
- Q37508315 P2093 "A William Blackstock" @default.
- Q37508315 P2093 "Anastasia Ivanova" @default.
- Q37508315 P2093 "Bert H O'Neil" @default.
- Q37508315 P2093 "Janine M Davies" @default.
- Q37508315 P2093 "Joel E Tepper" @default.
- Q37508315 P2093 "Laura Raftery" @default.
- Q37508315 P2093 "Mebea Aklilu" @default.
- Q37508315 P2093 "Richard M Goldberg" @default.
- Q37508315 P2093 "Stephen A Bernard" @default.
- Q37508315 P2860 Q33341477 @default.
- Q37508315 P2860 Q33346354 @default.
- Q37508315 P2860 Q33347089 @default.
- Q37508315 P2860 Q33369542 @default.
- Q37508315 P2860 Q33376728 @default.
- Q37508315 P2860 Q33384594 @default.
- Q37508315 P2860 Q36901251 @default.
- Q37508315 P2860 Q37621828 @default.
- Q37508315 P2860 Q40483649 @default.
- Q37508315 P2860 Q43145569 @default.
- Q37508315 P2860 Q46019139 @default.
- Q37508315 P2860 Q46827306 @default.
- Q37508315 P2860 Q46958960 @default.
- Q37508315 P2860 Q79907493 @default.
- Q37508315 P2860 Q80017697 @default.
- Q37508315 P304 "250-253" @default.
- Q37508315 P31 Q13442814 @default.
- Q37508315 P356 "10.1097/COC.0B013E3182467F22" @default.
- Q37508315 P433 "3" @default.
- Q37508315 P478 "36" @default.
- Q37508315 P577 "2013-06-01T00:00:00Z" @default.
- Q37508315 P698 "22547007" @default.
- Q37508315 P921 Q180507 @default.
- Q37508315 P921 Q422327 @default.